(Reuters) – China is intensifying its investigation into rampant bribery in the pharmaceutical and medical services sector with a fresh three-month probe slated to begin on Thursday, the official Xinhua news agency reported.
The investigation by the State Administration for Industry and Commerce (SAIC), a regulator in charge of market supervision, is aimed at stamping out bribery, fraud and other anti-competitive practices in various sectors, Xinhua said.
Read Full Article HERE
Kazunori Takada, Reuters via CHINA US Focus http://feedproxy.google.com/~r/ChinaUsFocus/~3/tsatuEVCQZ0/
No comments:
Post a Comment